Press Room

AAPS 2024 PharmSci 360

Start
Sunday, October 20, 2024
End
Wednesday, October 23, 2024
Location: Salt Lake City, United States
Booth Number: 1939
Hovione is present at AAPS in October 2024, know more about the event and contact us to schedule a meeting

Visit Hovione’s booth at AAPS PharmSci 360 next October 20-23 in Salt Lake City and meet our team of experts.

The AAPS PharmSci 360 Annual Meeting is organized by the American Association of Pharmaceutical Scientists (AAPS). The event provides a platform for pharmaceutical scientists from academia, industry, government, and other institutions worldwide to exchange knowledge and discuss the latest advancements in the field.

Don't miss our experts' presentations in Salt Lake City

Oral Presentation, 155 F

Development of Spray Drying Processes Grounded on Innovative Approaches
Monday, October 21 | 10:30 AM – 11:00 AM
Presenting Author: Clara Sa Couto, Ph.D.

Short description: New BCS Class 2 drugs represent up to 70% of the pharmaceutical pipeline. Limited aqueous solubility has been one of the major hurdles in the development of oral-dosage forms, as poor solubility hinders oral bioavailability. Different formulation strategies and enabling technologies have been used to overcome low aqueous solubility, including complexation with other compounds, nano-milling and amorphous solid dispersions (ASD).
ASDs have emerged has one of the preferred methods to improve solubility, with industrially demonstrated processes and multiple approved treatments. Generally, the ASDs manufacturing methods are classified into solvent-based – spray drying (SD), electrospraying, rotary evaporation – and melting or fusion – hot-melt extrusion, KinetiSol, Three-dimensional (3D) printing.

The selection of the most suitable method depends on the nature of the API and the SD has been unanimously recognized as the leading technology due to not only the mild processing conditions but also due to scalability, commercial scale representative ASD material can be produced in laboratorial scale and kept across scales. (full description)

Key learnings:

  • Develop a robust process at lab scale and assure a successful scale-up
  • Understand how to use of mathematical models, rheological and analytical characterization, and PAT tools to improve SD process development
  • Understand how to use a Model Based Methodology to Establish the Design Space and a Commercial Process

Rapid Fire Presentation, 155 E

Streamlining Loss-in-Weight Feeding Process Development Using Predictive Tools
Monday, October 21 | 3:30 PM – 4:30 PM
Presenting Author: João Henriques, M.Sc.

Short description: Continuous Direct Compression (CDC) has gained increased attention due to its advantages over batch processing. In CDC, each material is individually fed into the system at a predefined rate via loss-in-weight feeders, making it essential to understand their behavior during processing. This study aimed to predict the feeding performance and ideal setup for a new material, based on material properties. This was achieved by correlating material properties and feeder setup with feeding performance. A wide range of materials, including excipients, APIs, and spray-dried excipients, were physically and rheologically characterized, and their feeding performance evaluated. Results indicate that feeding performance is predominantly influenced by variables related to density, cohesion, and flowability, which can be obtained by performing three characterization analyses. In turn, these properties determine how different setup options influence feeding behavior. This workflow allows a data-driven approach, significantly reducing the time and material spent on process development.

Key learning: In this presentation, attendees will explore the potential of using predictive strategies to develop and optimize a loss-in-weight feeding process for continuous tableting using minimum analytical and rheological characterization.

 

Join Hovione at our poster presentations

Dispersome® as an Advanced Platform for Oral Bioenhancement

Monday, October 21 | 12:30 PM – 1:30 PM
Authors: Ana Filipa Ferreira Ph.D., Liliana Rodrigues Ph.D., Carolina Pinheiro Ph.D., Maria Paisana Ph.D., Emmanuel Heinrich Ph.D., Ines Ramos Ph.D., Sara Pinto M.Sc.
Presenting Author: João Henriques, M.Sc.

Improving Lipid Nanoparticles Stability for mRNA Lung Delivery Through Nebulization

Tuesday, October 22 | 9:30 AM – 10:30 AM
Authors: Ricardo Miguel Velez M.Sc., Eunice Costa Ph.D., Susana Saldanha Ph.D., Rute Mota M.Sc., Luís Marques Ph.D.
Presenting Author: Eunice Costa Ph.D.

Natural-Based ASD Platforms: Enhancing Stability and Bioavailability

Tuesday, October 22 | 9:30 AM – 10:30 AM
Authors: Francisco Tavares M.Sc., Clara Sa Couto Ph.D., Joana Cotrim B.Sc., Ines Ramos Ph.D., Vanda Serra Ph.D., Maria Paisana Ph.D.
Presenting Author: Clara Sa Couto, Ph.D.

Protein Stabilization Sweet Spot: Novel Class of Sugar-Based Excipients Enabling Downstream Processing and Formulation

Tuesday, October 22 | 12:30 PM – 1:30 PM
Authors: Paulo Roque Lino, Eva C. Lourenço, Joana Diogo, Ricardo Gonçalves, Osvaldo S. Ascenso, Joana Cristóvão, Ana Filipa Ferreira, Luís Marques Ph.D.
Presenting Author: Eunice Costa Ph.D.

 

Let’s discuss your project together.

schedule a meeting

 

 

 

Find more about AAPS PharmSci 360

 

 

You might be interested in:

Drug Substance at Hovione

Your partner in custom development and manufacturing of APIs.

The Leader in Spray Drying

Know how to overcome your solubility issues with the best scale-up science.

The Future is Continuous

Meet our experts and find out if Continuous Tableting is right for your product.

Industrialization of Innovative Platforms

Learn more about our Large-scale GMP-compliant platforms that support your project from development to commercialization. 

 

 

Also in the Press Room

See All

Hovione’s Eunice Costa Shares Insights on Inhaled Medicine Formulation in Pharmaceutical Technology eBook The demand for efficient inhalation therapies is higher than ever. At Hovione we are focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes.  To learn more about or work, do not miss the contribution of Eunice Costa, our R&D Director for Inhalation & Advanced Drug Delivery, in the latest Pharmaceutical Technology eBook – “Trends in Formulation”.  In her interview, Eunice discusses key challenges and considerations in formulating inhaled medicines, emphasizing the importance of excipient selection, device compatibility, and patient-centric design for successful drug delivery to the lungs. With respiratory diseases at the forefront, especially following the COVID-19 pandemic, the demand for efficient inhalation therapies is higher than ever. Eunice sheds light on how Hovione is tackling these demands by focusing on particle size, dispersion performance, and formulation integrity to ensure optimal bioavailability and patient outcomes. Explore Eunice Costa’s full insights on this crucial area of drug development in Pharmaceutical Technology's September 2024 eBook. This resource provides an in-depth look into the complexities of inhaled drug formulations and the exciting innovations shaping the future of respiratory treatments.   Read the full article at Pharmaceutical Technology eBook Read the Trends in Formulation eBook at PharmTech  

Article

Formulating Inhaled Medicines

Sep 24, 2024

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024